Education
About Us
Working with TipRanks
Follow Us
Defence Therapeutics (DTCFF)
OTHER OTC:DTCFF
Total Valuation
Defence Therapeutics has a market cap or net worth of $24.20M. The enterprise value is $32.39M.
Market Cap$24.20M
Enterprise Value$32.39M
Share Statistics
Defence Therapeutics has 54,725,370 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding54,725,370
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Defence Therapeutics’s return on equity (ROE) is 2.80 and return on invested capital (ROIC) is -1315.83%.
Return on Equity (ROE)2.80
Return on Assets (ROA)-2.13
Return on Invested Capital (ROIC)-1315.83%
Return on Capital Employed (ROCE)2.60
Revenue Per Employee0.00
Profits Per Employee-704.41K
Employee Count5
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Defence Therapeutics is ―. Defence Therapeutics’s PEG ratio is 0.13.
PE Ratio―
PS Ratio0.00
PB Ratio-27.77
Price to Fair Value-27.77
Price to FCF-10.26
Price to Operating Cash Flow―
PEG Ratio0.13
Income Statement
In the last 12 months, Defence Therapeutics had revenue of 0.00 and earned -3.52M in profits. Earnings per share was -0.07.
Revenue0.00
Gross Profit-72.34K
Operating Income-3.27M
Pretax Income-3.52M
Net Income-3.52M
EBITDA-3.13M
Earnings Per Share (EPS)-0.07
Cash Flow
In the last 12 months, operating cash flow was -3.40M and capital expenditures 823.33K, giving a free cash flow of -2.58M billion.
Operating Cash Flow-3.40M
Free Cash Flow-2.58M
Free Cash Flow per Share-0.05
Dividends & Yields
Defence Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.47
52-Week Price Change-47.50%
50-Day Moving Average0.52
200-Day Moving Average0.55
Relative Strength Index (RSI)40.00
Average Volume (3m)599.00
Important Dates
Defence Therapeutics upcoming earnings date is Mar 3, 2026, After Close (Confirmed).
Last Earnings DateNov 27, 2025
Next Earnings DateMar 3, 2026
Ex-Dividend Date―
Financial Position
Defence Therapeutics as a current ratio of 0.50, with Debt / Equity ratio of ―
Current Ratio0.50
Quick Ratio0.50
Debt to Market Cap0.04
Net Debt to EBITDA-0.09
Interest Coverage Ratio-10.14
Taxes
In the past 12 months, Defence Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Defence Therapeutics EV to EBITDA ratio is -11.24, with an EV/FCF ratio of -10.34.
EV to Sales0.00
EV to EBITDA-11.24
EV to Free Cash Flow-10.34
EV to Operating Cash Flow-10.34
Balance Sheet
Defence Therapeutics has $1.23M in cash and marketable securities with $2.97M in debt, giving a net cash position of -$271.84K billion.
Cash & Marketable Securities$1.23M
Total Debt$2.97M
Net Cash-$271.84K
Net Cash Per Share>-$0.01
Tangible Book Value Per Share-$0.03
Margins
Gross margin is ―, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin―
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Defence Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―